Relebactam
| Structural formula | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
||||||||||||||||
| General | ||||||||||||||||
| Non-proprietary name | Relebactam | |||||||||||||||
| other names |
(2 S , 5 R ) -7-Oxo-N- (4-piperidinyl) -6- (sulfooxy) -1,6-diazabicyclo [3.2.1] octane-2-carboxamide ( IUPAC ) |
|||||||||||||||
| Molecular formula | C 12 H 20 N 4 O 6 S | |||||||||||||||
| External identifiers / databases | ||||||||||||||||
|
||||||||||||||||
| properties | ||||||||||||||||
| Molar mass | 348.37 g mol −1 | |||||||||||||||
| Physical state |
firmly |
|||||||||||||||
| safety instructions | ||||||||||||||||
|
||||||||||||||||
| As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions . | ||||||||||||||||
Relebactam is an antibiotic drug from the group of β-lactamase inhibitors .
application
Relebactam was approved in a fixed combination with imipenem and cilastatin in the USA in July 2019 for the treatment of
- hospital-acquired bacterial pneumonia (hospital-acquired bacterial pneumonia , HABP) and bacterial pneumonia a ventilated patient ( ventilator-associated bacterial pneumonia , VABP) in adults,
- complicated urinary tract infections ( complicated urinary tract infection , CUTI), including pyelonephritis in adults for which limited or no alternative treatment options are available,
and which are caused by correspondingly sensitive gram-negative germs.
Others
Relebactam is used pharmaceutically as a monohydrate , a crystalline white to almost white, water-soluble powder.
Individual evidence
- ↑ a b Mk-7655 (cas 1174018-99-5). In: caymanchem.com. Retrieved January 23, 2020 (English).
- ↑ a b RECARBRIO imipenem anhydrous, cilastatin, and relebactam anhydrous injection, powder, for solution. DailyMed, accessed January 23, 2020 .
- ↑ Krisztina M. Papp-Wallace, Melissa D. Barnes, Jim Alsop, Magdalena A. Taracila, Christopher R. Bethel, Scott A. Becka, David van Duin, Barry N. Kreiswirth, Keith S. Kaye, Robert A. Bonomo: Relebactam Is a Potent Inhibitor of the KPC-2 β-Lactamase and Restores Imipenem Susceptibility in KPC-Producing . In: Antimicrobial Agents and Chemotherapy . tape 62 , no. June 6 , 2018, doi : 10.1128 / AAC.00174-18 ( nih.gov ).
- ↑ Novel Drug Approvals for 2019. US Food & Drug Administration (FDA), January 14, 2020, accessed on January 23, 2020 .
- ↑ External identifiers of or database links to relebactam monohydrate : CAS number: 1174020-13-3, EC number: 813-387-3 , ECHA InfoCard: 100.245.825 , PubChem : 76900350 , ChemSpider : 31389941 , Wikidata : Q27294146 .